

Korea's SK Pharmteco to invests \$100M to bolster global gene therapy business

March 23, 2026 | News

Aims to reinforce and expand the company's viral vector business through centers of excellence in King of Prussia, Pennsylvania, and Corbeil-Essonnes, France



SK pharmteco is embarking into strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors.

A significant funding commitment of \$100 million USD will be deployed to reinforce and expand the company's viral vector business. This investment will target its centers of excellence in King of Prussia, Pennsylvania, and Corbeil-Essonnes, France, to advance its strategy.

SK pharmteco is sharpening its strategy to provide pharmaceutical and biotechnology partners with the financial strength, technical rigor, and operational infrastructure needed for long-term success across multiple modalities. The company continues to expand its small molecule and peptide businesses while reinforcing its commitment to viral vector development and manufacturing, and believes this three-business-unit approach positions SK pharmteco as a versatile CDMO partner for biopharma companies managing increasingly diverse pipelines, from established therapeutics to advanced therapies.

SK pharmteco is prioritizing operational excellence with a focus on further maturing quality systems, optimizing process performance, and advancing technology transfer while enabling innovation across its global network to deliver more reliable development, late-stage, and commercial execution.

"Our strategy is built on the strength of three essential business units: small molecules, peptides, and viral vectors," said Joerg Ahlgrimm, Chief Executive Officer of SK pharmteco. "As the industry evolves, our partners need a CDMO that combines specialized expertise, technical sophistication, and operational reliability across modalities. This commitment supports our continued efforts to strengthen our viral vector business while advancing the broader capabilities, quality, and commercial readiness that customers expect across our global network."

By advancing its three-business-unit strategy, SK pharmteco is strengthening its position as a differentiated global CDMO, combining the reliability and scale of established small molecule manufacturing, the specialized capabilities of its peptides business, and the advanced expertise required to support the development and manufacture of viral vector-based therapies.